Flosonics Medical is a Canadian medical device company (founded 2015, Sudbury, Ontario) that develops FloPatch, a wireless wearable Doppler ultrasound designed to deliver rapid, repeatable hemodynamic assessments at the bedside. FloPatch aims to help clinicians assess fluid responsiveness and streamline critical decisions in sepsis and other acute-care settings, reducing fluid-related complications and improving patient outcomes. The company positions the device as a faster, more accessible alternative to traditional Doppler ultrasound machines in emergency and intensive care environments. Flosonics says the funding will accelerate market adoption and enable broader hospital deployment across North America and beyond. The announcement highlights the company’s focus on non-invasive, data-driven solutions and ongoing clinical research to support its technology. Financially, Flosonics secured venture debt to support scaling operations and commercialization efforts. Flosonics Medical develops FloPatch, a first-in-class wearable Doppler ultrasound designed for hemodynamic assessments. The device is intended to improve management of critically ill patients and support monitoring both inside and outside the hospital. The company emphasizes continued evidence generation to validate clinical use. Flosonics plans to expand indications for use and accelerate commercial growth and market adoption. The firm is a Canadian medical device company based in Sudbury, Ontario, founded in 2015. Recent financing will be used to support innovation, expansion, and broader deployment of its wearable AI-assisted sensor technology. Flosonics Medical is a venture-backed medical device company developing the FloPatch, a low-cost, wearable Doppler ultrasound sensor that adheres to a patient’s neck and sends hands-free blood flow data wirelessly via low-energy Bluetooth. The company says FloPatch enables on-demand, non-invasive Doppler measurement of blood flow to support management of critically ill patients across emergency, OR, ward, and ICU settings. Its first product, the FloPatch FP 120, has received regulatory clearances from the FDA and Health Canada. Founded in 2015 and headquartered in Sudbury, Ontario, Flosonics employs over 20 people focused on R&D. Financing proceeds will be used for a commercial launch in North America and for new product development as the technology transitions to clinical use.

Total raised

$40M

Funding rounds

3

Latest round

Debt Financing

Latest activity

Mar 2025